Introduction
============

On tumor necrosis factor-α (TNF-α) binding, TNF receptor 1 (TNFR1) triggers the intracellular assembly of the so-called TNFR complex I, which includes TNF receptor--associated death domain, receptor-interacting protein kinase 1 (RIPK1), cellular inhibitor of apoptosis proteins (cIAPs), and TNF receptor--associated factor 2 (TRAF2; [@bib29]). Within the complex, RIPK1 is polyubiquitinated by several ubiquitin ligases including cIAPs, which further recruits TGF-β--activated kinase 1 (TAK1) and IκB kinase (IKK), leading to the activation of nuclear factor-κB (NF-κB) and transactivation of cytoprotective genes such as cellular FLICE-like inhibitory protein (c-FLIP) to facilitate cell survival ([@bib11]). The molecular composition of the TNFR1 complex is subsequently changed and leads to the formation of protein complex II, the so-called cell death-inducing signaling complex (DISC; [@bib29]). In complex II, RIPK1, an adaptor molecule, Fas-associated death domain (FADD), and caspase-8 activate the pro-apoptotic caspase activation cascade ([@bib52]). RIPK1 is de-ubiquitinated by de-ubiquitination enzymes such as CYLD concomitantly with the formation of complex II ([@bib56]; [@bib36]). If caspases are inhibited or CYLD is hyperactivated, complex II cannot execute apoptosis but triggers phosphorylation and activation of RIPK1 and RIPK3 to initiate necrotic cell death ([@bib17]; [@bib52]; [@bib60]; [@bib11]; [@bib37]; [@bib36]; [@bib51]). Catalytic activity of RIPK1 is not required for complex I--induced pro-survival signaling ([@bib6]), whereas RIPK1 activation is required for RIPK3 activation and necrotic cell death ([@bib7]). In addition, when RIPK1 is activated by down-regulation of cIAP, RIPK1 induces not only necrosis but also caspase activation and apoptosis ([@bib56]; [@bib10]; [@bib49]; [@bib9]). However, relatively little is known about the regulations by which RIPK1 activates RIPK3 and/or caspases.

TAK1 is a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family that is activated by inflammatory cytokines such as IL-1, TNF, or Toll-like receptor ligands ([@bib34]; [@bib14]). TAK1 is known to be essential for prevention of TNF-induced cell death in both in vitro and in vivo settings ([@bib39]; [@bib22]; [@bib19]; [@bib59]; [@bib31]). *Tak1*-deficient cells are hypersensitive to TNF-induced cell death due to diminished pro-survival pathways including loss of NF-κB activation and reduced antioxidant enzymes, which results in activation of caspases ([@bib40]; [@bib30]; [@bib1]; [@bib53]; [@bib26]). It has been recently reported that inhibition of RIPK1 blocks caspase activation and cell death in *Tak1*-deficienct cells ([@bib1]; [@bib53]; [@bib26]), suggesting that TNF-induced TAK1 activation inhibits RIPK1-induced caspase activation. TNF-induced activation of TAK1 is transient, peaking at 5--10 min, and quickly deactivated by type 2 protein phosphatases such as protein phosphatases 2A and 6 (PP2A and PP6; [@bib21]; [@bib23]; [@bib4]), which is sufficient to activate the cytoprotective pathways. We have recently discovered that a binding partner of TAK1, TAK1-binding protein 2 (TAB2), is essential for TAK1 deactivation by recruiting PP6 to the TAK1 complex, and that ablation of TAB2 causes hyperactivation of TAK1 in fibroblasts ([@bib4]). Here we report that hyperactivation of TAK1 unexpectedly induces RIPK3-dependent cell death.

Results
=======

*Tab2* deficiency causes necrotic cell death
--------------------------------------------

*Tab2*-deficient fibroblasts show enhanced and prolonged TAK1 activation after TNF stimulation ([Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201305070/DC1){#supp1}; [@bib4]). Because TAK1 has a protective role to inhibit TNF-induced cell death, we initially anticipated that *Tab2* deletion would be protective in TNF-induced cell death. However, to our surprise, we found that *Tab2*-deficient fibroblasts were also sensitive to TNF-induced cell death ([Fig. 1 A](#fig1){ref-type="fig"}). To understand the mechanism of TNF-induced cell death in *Tab2*-deficient fibroblasts, we compared cell death in *Tab2*-deficient fibroblasts with that in *Tak1*-deficient fibroblasts. We found that TNF-induced cell death in *Tab2*-deficient fibroblasts exhibited characteristics different from those by *Tak1* deficiency. TNF stimulation up-regulated activity of caspase-3 and caspase-8 in *Tak1*-deficient fibroblasts within 6 h after stimulation ([Fig. 1 B](#fig1){ref-type="fig"}). In contrast, *Tab2*-deficient fibroblasts did not show a pronounced increase in caspase activation ([Fig. 1 B](#fig1){ref-type="fig"}), even though they were already morphologically disrupted at 6 h after TNF stimulation (Fig. S1 B). These results suggest that TNF causes caspase-independent cell death in *Tab2*-deficient fibroblasts. We examined morphology of TNF-treated *Tak1*-deficient and *Tab2*-deficient fibroblasts by transmission electron microscopy in order to understand the type of cell death they undergo. *Tak1*-deficient fibroblasts exhibited the characteristic morphological features associated with apoptosis such as plasma membrane blebbing, whereas *Tab2*-deficient fibroblasts exhibited the features associated with necrosis such as plasma membrane rupture, translucent cytoplasm, and organelle swelling ([Fig. 1 C](#fig1){ref-type="fig"} and Fig. S1 C). These results suggest that *Tak1* deficiency causes TNF-induced apoptosis, whereas *Tab2* deficiency causes necrotic cell death.

![***Tab2*-deficient fibroblasts are sensitive to TNF-induced cell death.** (A) *Tab2* wild-type (*Tab2* WT) and -deficient (*Tab2* KO) fibroblasts were seeded on 24-well plates and treated with 2, 20, or 200 ng/ml of TNF for 24 h. Cells attached on the plates were determined by the crystal violet assay. Values of unstimulated fibroblasts were set at 100%. The x axis is a log scale (five independent experiments; mean ± SD; \*\*\*, P = 0.00002). (B) *Tak1* wild-type (*Tak1* WT), -deficient (*Tak1* KO), *Tab2* WT, and *Tab2* KO fibroblasts were pretreated with vehicle (DMSO) or pan-caspase inhibitor, Z-VAD(OMe)FMK (Z-VAD; 20 µM) for 1 h and stimulated with TNF (20 ng/ml for *Tak1* fibroblasts or 200 ng/ml for *Tab2* fibroblasts) for 6 h. Caspase-3 was analyzed by immunoblotting. Immunoblots of TAK1, TAB2, and β-actin are shown as controls. *Tak1* KO fibroblasts express a truncated (kinase-negative) form of TAK1 (TAK1Δ). Asterisk indicates a nonspecific band. Caspase-8 activity in cellular extracts from samples treated with the same procedure was measured. Data are shown as caspase-8 activity relative to that in unstimulated *Tak1* WT samples (three independent experiments; mean ± SD; one-way ANOVA; \*\*, P \< 0.01; N.S., not significant, P = 0.0013 and P = 0.59 from the left). (C) *Tak1 KO* and *Tab2 KO* fibroblasts were exposed to TNF (20 ng/ml for *Tak1* KO and 200 ng/ml for *Tab2* KO) for 6 h and samples were analyzed using a transmission electron microscope. Bars, 2 µm.](JCB_201305070_Fig1){#fig1}

We previously reported that the pan-caspase inhibitor Z-VAD(OMe)-FMK (Z-VAD) could block cell death in *Tak1*-deficient keratinocytes at 2--4 h after TNF stimulation ([@bib40]). To examine whether caspase is responsible for the cell death in *Tak1*-deficient dermal fibroblasts, we treated cells with Z-VAD. Z-VAD partially rescued cell death at an early time point (6 h) after TNF stimulation in *Tak1*-deficient cells (Fig. S1 B), which is consistent with the study in keratinocytes. However, we found that Z-VAD did not rescue the cell death in *Tak1*-deficient cells after 24 h (Fig. S1 D). Caspase inhibition might activate TNF-induced necrosis in *Tak1*-deficient cells, which is consistent with previous studies showing that Z-VAD does not block but rather induces TNF-induced necrotic cell death ([@bib13]).

TNF-induced cell death in *Tab2*-deficient fibroblasts requires RIPK1 activity
------------------------------------------------------------------------------

RIPK1 catalytic activity is generally implicated in necrotic cell death in TNF signaling pathways ([@bib52]; [@bib60]). Necrotic morphology seen in TNF-treated *Tab2*-deficient fibroblasts prompted us to investigate the involvement of RIPK1. Treatment of *Tab2*-deficient fibroblasts with a specific inhibitor of RIPK1 kinase, necrostatin-1 (Nec-1), completely blocked TNF-induced cell death, indicating that *Tab2* deficiency causes RIPK1-dependent cell death in response to TNF ([Fig. 2 A](#fig2){ref-type="fig"}). Although *Tak1*-deficient cells showed apoptotic morphology in response to TNF, Nec-1 also blocked TNF-induced cell death in *Tak1*-deficient fibroblasts ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201305070/DC1){#supp2}), consistent with previous studies ([@bib1]; [@bib53]; [@bib26]). This rescue effect may be caused by an inhibitory effect of Nec-1 on apoptosis, as RIPK1 catalytic activity was previously shown to be also required for induction of apoptosis ([@bib54]). Consistently, Nec-1 inhibited TNF-dependent caspase-3 and caspase-8 activation in *Tak1*-deficient cells, whereas *Tab2* deficiency did not induce TNF-induced caspase activation ([Fig. 2 B](#fig2){ref-type="fig"}). *Tab2*-deficient fibroblasts undergo RIPK1-dependent cell death without engaging caspase activation, whereas *Tak1*-deficient fibroblasts die with RIPK1-dependent caspase activation.

![**TNF-induced cell death in *Tab2*-deficient cells is rescued by inhibition of RIPK1.** (A) *Tab2* WT and *Tab2* KO fibroblasts were pretreated with either vehicle (DMSO) or Nec-1 (30 µM) for 1 h, and then treated with 2, 20, or 200 ng/ml of TNF for 24 h. Cells attached on the plates were determined by the crystal violet assay. Values of unstimulated fibroblasts were set at 100%. The x axis is a log scale (three independent experiments; mean ± SD; \*\*, P = 0.0066). (B) *Tak1* KO and *Tab2* KO fibroblasts were pretreated with vehicle (DMSO) or Nec-1 (30 µM) for 1 h and stimulated with TNF (20 ng/ml for *Tak1* fibroblasts or 200 ng/ml for *Tab2* fibroblasts) for 0, 3, 6, and 9 h. Caspase-3 was analyzed by immunoblotting. Immunoblots of TAK1, TAB2, and β-actin are shown as controls. Asterisk indicates a nonspecific band. Caspase-8 activity in cellular extracts from samples treated with the same procedure was measured. Data are shown as caspase-8 activity relative to that in unstimulated *Tak1* KO samples (three independent experiments; mean ± SD; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; N.S., not significant; P = 0.012, P = 0.00016, P = 0.0012, P = 0.97, P = 0.99, and P = 0.33 from the left).](JCB_201305070_Fig2){#fig2}

*Tab2*-deficient fibroblasts die with RIPK3-dependent necrosis
--------------------------------------------------------------

RIPK3 has been shown to interact with RIPK1 and induce necrotic cell death ([@bib52]; [@bib60]; [@bib11]; [@bib37]; [@bib51]). Thus, we examined whether RIPK3 is required for TNF-induced cell death in *Tab2*-deficient fibroblasts. *Ripk3* knockdown effectively blocked TNF-induced cell death in *Tab2*-deficient fibroblasts ([Fig. 3 A](#fig3){ref-type="fig"}). To confirm this result, we generated *Tab2* and *Ripk3* double-deficient mice using a ubiquitously expressing inducible Cre transgene system, *Rosa26-CreERT* ([@bib2]). Dermal fibroblasts were isolated from *Rosa26-CreERT Tab2^flox/flox^ Ripk3^−/−^* and control mice, and *Tab2* deletion was induced in vitro by a *CreERT* activator, 4-hydroxytamoxifen. *Tab2* and *Ripk3* double-deficient fibroblasts were found to be resistant to TNF-induced cell death (Fig. S2 B). Thus, TNF-induced cell death in *Tab2*-deficient fibroblasts is RIPK3 dependent. In contrast, ablation of *Ripk3* did not block TNF-induced cell death in *Tak1*-deficient fibroblasts ([Fig. 3 B](#fig3){ref-type="fig"}), and caspase activation in *Tak1*-deficient fibroblasts was not reduced by *Ripk3* knockdown ([Fig. 3 C](#fig3){ref-type="fig"}). These results suggest that TNF induces RIPK1--RIPK3-dependent cell death in *Tab2*-deficient fibroblasts, whereas *Tak1* deficiency engages RIPK3-independent cell death.

![***Ripk3* knockdown rescues TNF-induced cell death in *Tab2*-deficient but not *Tak1*-deficient fibroblasts.** (A) *Tab2* WT and *Tab2* KO fibroblasts were transfected with *Ripk3* siRNA \#1 and \#2 and stimulated with 50, 100, or 200 ng/ml of TNF at 72 h after transfection. The protein levels of RIPK3 were determined by immunoblotting. Cell viability was determined at 24 h after TNF stimulation by the crystal violet assay. Values of unstimulated fibroblasts were set at 100%. The x axis is a log scale (three independent experiments; mean ± SD; \*\*\*, P \< 0.001; P = 0.026 and P = 0.000024 from the bottom). (B) *Tak1* WT and *Tak1* KO fibroblasts were transfected with *Ripk3* siRNA \#2, and stimulated with 0.2, 2, or 20 ng/ml of TNF at 72 h after transfection. Cell viability was determined at 24 h after TNF stimulation by the crystal violet assay. Values of unstimulated fibroblasts were set at 100%. The x axis is a log scale (three independent experiments; mean ± SD; N.S., not significant; P = 0.99). (C) *Tak1* KO fibroblasts were transfected with *Ripk3* siRNA \#2, and stimulated with 20 ng/ml TNF at 72 h after transfection. Caspase-3 was analyzed by immunoblotting. Immunoblots of RIPK3 and β-actin are shown as controls.](JCB_201305070_Fig3){#fig3}

To investigate the role of TAB2 in vivo, we used the inducible *Tab2* deletion (*Rosa26-CreERT Tab2^flox/flox^*) mice and generated *Tab2*-deficient mice by treatment of a CreERT activator, tamoxifen. We confirmed that TAB2 protein was diminished by the gene deletion ([Fig. 4 A](#fig4){ref-type="fig"}). Because our fibroblasts were isolated from the dermal layer of the skin, we intradermally injected TNF to examine whether our results in culture cells can be reproduced in the in vivo skin ([Fig. 4 B](#fig4){ref-type="fig"}). We found that *Tab2*-deficient mice exhibited extensive cell death in the dermal fibroblasts in vivo*,* which was rescued by *Ripk3* deletion ([Fig. 4 B](#fig4){ref-type="fig"}). This demonstrates that TNF induces RIPK3-dependent cell death in *Tab2*-deficient mice in vivo. To further examine the relationship between TAB2 and RIPK3 in vivo, we performed a wound-healing assay. The wound-healing process is characterized by regeneration of the cellular and extracellular components of the skin. This process involves inflammation, proliferation, and remodeling ([@bib58]). The proliferative phase of healing includes the re-epithelialization of the superficial surface layer and the reconstitution of the underlying dermis by dermal fibroblasts. Upon cutaneous injury, TNF is known to be secreted by immune cells ([@bib58]). Thus, we hypothesized that *Tab2* deficiency in dermal fibroblasts would induce cell death upon skin injury, which would delay the wound-healing process. Indeed, *Tab2*-deficient mice showed slower wound healing compared with wild-type mice, and the delay in *Tab2*-deficient mice was rescued by *Ripk3* deletion ([Fig. 4 C](#fig4){ref-type="fig"}). TUNEL-positive dermal fibroblasts were increased in the injured *Tab2*-deficient skin, which was also reduced by *Ripk3* deletion ([Fig. 4 D](#fig4){ref-type="fig"}). Thus, TAB2 participates in skin wound healing in vivo by preventing RIPK3-dependent cell death.

![***Ripk3* deletion rescues cell death in the *Tab2*-deficient skin in vivo.** (A) *Rosa26-CreERT* *Tab2^flox/+^ Ripk3^−/−^, Rosa26-CreERT Tab2^flox/flox^*, and *Rosa26-CreERT Tab2^flox/flox^ Ripk3^−/−^* mice were treated with tamoxifen at 50 mg/kg for three consecutive days to generate *Tab2* Het *Ripk3* KO, *Tab2* KO, and *Tab2 Ripk3* DKO, respectively. *Tab2^flox/flox^* mice were treated with the same dose of tamoxifen and studied in parallel as *Tab2* WT. 2 wks after the injection, protein extracts from spleen were isolated to confirm the deletion of *Tab2* gene by immunoblotting. RIPK3 and β-actin are shown as controls. (B) 1 µg TNF was intradermally injected in *Tab2* WT (*n* = 3), *Tab2* KO (*n* = 3), and *Tab2 Ripk3* DKO mice (*n* = 3). After 6 h, the skin was isolated and TUNEL staining was conducted on the sections. The arrows indicate TUNEL-positive dermal fibroblasts. epi, epidermis; der, dermis. Bars, 40 µm. The percentages of TUNEL-positive cells in the dermal fibroblasts are shown (mean ± SD; \*\*, P \< 0.01; P = 0.0018, P = 0.0035, and P = 0.0027 from the left). (C and D) Skin wound surgery was conducted on *Tab2* WT (*n* = 6), *Tab2* KO (*n* = 5), *Tab2* Het *Ripk3* KO (*n* = 4), and *Tab2 Ripk3* DKO (*n* = 5) mice. Wound area was expressed as a percentage of initial wound size. Statistical significance between *Tab2* WT and *Tab2* KO or between *Tab2* KO and *Tab2 Ripk3* DKO is indicated by ^\#^ or \*, respectively (mean ± SD; ^\#\#^ and \*\*, P \< 0.01; ^\#^ and \*, P \< 0.05; ^\#^, P = 0.034; ^\#^, P = 0.011; ^\#^, P = 0.014; ^\#^, P = 0.045; ^\#^, P = 0.038; ^\#^, P = 0.027; \*\*, P = 0.0042; \*\*, P = 0.0022; \*\*, P = 0.01; \*, P = 0.030; and \*, P = 0.028 from the left). 4 d after skin surgery, the skin was isolated from the mice and TUNEL staining was conducted on the sections (D). Arrows indicate TUNEL-positive cells. epi, epidermis; der, dermis; scab, a scab formed over the wound. Bars, 40 µm.](JCB_201305070_Fig4){#fig4}

We next examined the effect of *Ripk3* deletion on TNF-induced cell death in a *Tak1*-deficient tissue in vivo. Because whole-body *Tak1*-deficient mice die within several days after gene deletion ([@bib48]), we used mice having hepatocyte-specific deletion of *Tak1*, which is known to develop TNF-dependent liver damage by 1--2 months of age ([@bib3]; [@bib19]). We generated mice with liver parenchymal cell-specific deletion of *Tak1* (*TAK1^LPC-KO^*) in either a *Ripk3^−/−^* or a *Tnfr1^−/−^* background to determine the contribution of RIPK3 to TNF-mediated liver damage. *Tak1* deficiency caused pronounced liver injury involving TUNEL-positive cells, and highly increased alanine aminotransferase (ALT) levels in serum and the activity of caspase-3 and caspase-8 in liver extracts ([Fig. S3, A--C](http://www.jcb.org/cgi/content/full/jcb.201305070/DC1){#supp3}), which is consistent with the earlier studies ([@bib3]; [@bib19]). Whereas ablation of TNF signaling diminished injury in *Tak1*-deficient livers, *Ripk3* deficiency did not restore them (Fig. S3, A--C). Thus, liver damage in *Tak1*-deficient mice is TNF dependent but RIPK3 independent. To further analyze the role of RIPK3 in *Tak1*-deficient cell death in vivo, we used the LPS-induced acute hepatotoxicity injury model, as LPS injection induces TNF-dependent hepatocyte toxicity ([@bib27]). Although *TAK1^LPC-KO^* mice spontaneously develop severe liver injury by 1--2 months of age, older *TAK1^LPC-KO^* mice have milder liver damage for unknown reasons ([@bib3]; [@bib19]). In the acute toxicity assay, we used relatively aged (4--7 months old) mice to avoid having a high basal level of liver damage without LPS stimulation. LPS highly elevated hepatocyte death and damage in *Tak1*-deficient mice compared with control mice, and the liver damage was not rescued by *Ripk3* deficiency (Fig. S3, D and E). These results demonstrate that RIPK3 has little contribution to cell death in *Tak1*-deficient cells in vivo as well as in vitro.

Enforced activation of TAK1 induces RIPK3-dependent cell death
--------------------------------------------------------------

In an effort to determine the mechanism by which *Tab2* deficiency activates TNF-induced RIPK3-dependent cell death, we focused on hyperactivation and sustained activation of TAK1 and asked whether it is the cause of RIPK3-dependent cell death. We used HeLa cells because they are highly transfectable and known to be deficient in RIPK3 expression ([@bib15]). We activated TAK1 using TAK1-binding protein 1 (TAB1), which is a constitutively associated TAK1 binding partner, and co-overexpression of TAK1 and TAB1 highly activates TAK1 ([@bib24]). TAK1 and TAB1 were overexpressed in the presence and absence of RIPK3 in HeLa cells, which were analyzed for cell death ([Fig. 5](#fig5){ref-type="fig"}). Activation of TAK1 or expression of RIPK3 alone did not profoundly induce cell death but RIPK3 moderately increased annexin V-- and cell permeability dye double-positive necrotic cell death in the presence of treatment with TNF together with an inhibitor of cIAP, Smac mimetic ([@bib56]), and Z-VAD (T/S/Z) treatment ([Fig. 5 A](#fig5){ref-type="fig"}), which is consistent with the earlier study ([@bib15]). However, when TAK1 and TAB1 were coexpressed with RIPK3, cell death was dramatically enhanced ([Fig. 5 A](#fig5){ref-type="fig"}). We also reproduced this result in mouse dermal fibroblasts. Overexpression of TAK1 and TAB1 or RIPK3 alone only marginally increased necrotic cell death in dermal fibroblasts, but overexpression of TAK1, TAB1, and RIPK3 together highly enhanced cell death ([Fig. S4](http://www.jcb.org/cgi/content/full/jcb.201305070/DC1){#supp4}). Overexpression of TAK1 and TAB1 produces an active form of TAK1 and we found that it induced a slower migrating additional RIPK3 band ([Fig. 5 B](#fig5){ref-type="fig"}). The retardation of RIPK3 migration was abolished by lambda phosphatase treatment ([Fig. 5 C](#fig5){ref-type="fig"}), suggesting that RIPK3 is phosphorylated by TAK1. We then examined whether TAK1 activates RIPK3 by the in vitro kinase assay ([Fig. 5 D](#fig5){ref-type="fig"}). An active and kinase-dead TAK1, RIPK3, and kinase-dead RIPK3 were prepared from HEK293 cells separately overexpressing these proteins, and proteins were mixed as indicated and subjected to in vitro kinase assay. Kinase activity was assessed by its autophosphorylation of RIPK3. RIPK3 was basally active (lane 3), which is consistent with an earlier study ([@bib5]), and the activity was further increased by TAK1 (lane 4). The kinase-dead RIPK3 was not detectably phosphorylated by TAK1 (lane 7). Thus, phosphorylation of wild-type RIPK3 (lanes 3--5) is likely to be predominantly mediated by RIPK3 autophosphorylation. We note that endogenous RIPK1 was co-precipitated with RIPK3 ([Fig. 5 D](#fig5){ref-type="fig"}, far right panels). This raises the possibility that co-precipitated RIPK1 in the RIPK3 preparation may be involved in activity of RIPK3 in these in vitro assays. However, endogenous RIPK1 was not coprecipitated with TAK1 ([Fig. 5 D](#fig5){ref-type="fig"}, second from right panels), indicating that adding TAK1 preparation to the kinase assay mixture did not increase total amount of RIPK1. Thus, the increase of RIPK3 activity (lane 4) over basal RIPK3 activity (lane 3) is mediated by TAK1 but not due to increase amount of RIPK1. These data demonstrate that an active TAK1 activates RIPK3, leading to necrosis.

![**Hyperactivation of TAK1 promotes RIPK3-dependent cell death.** (A) HeLa cells were transfected with 1 µg of Flag-TAB1 (TAB1), DsRedMT7-TAK1 (TAK1), HA-RIPK3 (RIPK3), or their control vectors for the total amount of 3 µg. At 48 h after transfection, cells were stimulated with 200 ng/ml TNF, 1 µM Smac mimetic, and 20 µM Z-VAD (T/S/Z) for 6 h. DsRed-positive transfected cells were gated, and cell death was analyzed by annexin V and fixable viability dye eFlour 780 staining. Percentages of fixable viability dye--positive cells in the transfected cells are shown (three independent experiments; mean ± SD; \*\*, P \< 0.01; P = 0.0043 and P = 0.0011 from the left). (B) HeLa cells were transfected as shown in A and treated with 200 ng/ml TNF alone or together with 1 µM Smac mimetic and 20 µM Z-VAD (S/Z). Activity of TAK1 was monitored by immunoblotting with anti-phospho-TAK1. Expression levels of TAB1, TAK1, RIPK1, and RIPK3 were also analyzed. β-Actin is shown as a control. (C) HeLa cells were transfected with expression vectors for RIPK3 with TAB1 and TAK1. Cell lysates were incubated with lambda protein phosphatase. Mobility shift of RIPK3 was observed by immunoblotting. β-Actin is shown as a control. (D) The Flag-tagged TAK1 wild-type (TAK1) or kinase-dead (TAK1 KD) TAK1 together with T7-tagged TAB1 (TAB1) and GFP-tagged wild-type (RIPK3) or kinase-dead (D161N; RIPK3 KD) RIPK3 were separately expressed in HEK293 cells. TAK1--TAB1 complex and RIPK3 were immunoprecipitated with anti-Flag or anti-RIPK3 antibody, respectively. TAK1--TAB1 complex was released from antibody beads, activated by incubation with ATP, and then mixed with RIPK3 or RIPK3 KD. RIPK3 kinase activity was assessed by in vitro kinase assay. Left panel, autoradiograph; right panels, immunoblot analysis of the immunoprecipitates with anti-TAK1 and anti-RIPK3 antibodies. Co-precipitated endogenous TAK1 and RIPK1 in the protein preparations were also determined by immunoblotting (right panels). Because HEK293 cells do not express RIPK3, endogenous RIPK3 was not examined.](JCB_201305070_Fig5){#fig5}

TAK1 mediates TNF-induced cell death in *Tab2*-deficient cells
--------------------------------------------------------------

The results shown in Fig. S1 demonstrate that *Tab2* deficiency induces hyperactivation of TAK1, which might be the cause of TNF-induced RIPK3-dependent cell death in *Tab2*-deficient fibroblasts. If *Tab2* deficiency mediates TNF-induced cell death through enhanced TAK1 activity, inhibition of TAK1 should rescue the TNF-dependent cell death in *Tab2*-deficient cells. To address this, we generated inducible *Tab2* and *Tak1* double-deficient mice (*Rosa26-CreERT Tab2^flox/flox^ Tak1^flox/flox^*), and dermal fibroblasts were isolated and used for the experiments. However, we found that *Tak1* and *Tab2* double-deficient fibroblasts still died ([Fig. 6 A](#fig6){ref-type="fig"}) and caspase activity was increased in response to TNF ([Fig. 6 B](#fig6){ref-type="fig"}), resembling *Tak1* single-deficient fibroblasts. We confirmed these results by using a selective TAK1 inhibitor, 5Z-7-Oxozeaenol (Zeaenol; [Fig. 6 C](#fig6){ref-type="fig"}). Thus, inhibition of TAK1 activates apoptosis and does not rescue TNF-induced cell death in *Tab2*-deficient fibroblasts. To overcome this difficulty, we attempted to block TNF-induced apoptosis. TNF-induced NF-κB activation is known to be impaired in *Tak1*-deficient cells ([@bib45]; [@bib40]), and NF-κB is an inducer of anti-apoptotic proteins such as c-FLIP ([@bib41]). Based on these data, we stably overexpressed an NF-κB protein, p65, in *Tak1*- or/and *Tab2*-deficient fibroblasts ([Fig. 6 D](#fig6){ref-type="fig"}). p65 overexpression increased c-FLIP in *Tak1*-deficient fibroblasts ([Fig. S5](http://www.jcb.org/cgi/content/full/jcb.201305070/DC1){#supp5}). As anticipated, p65 overexpression blocked TNF-induced cell death in *Tak1*-deficient fibroblasts ([Fig. 6 E](#fig6){ref-type="fig"}). Thus, enforced activation of NF-κB can block TNF-induced apoptosis in *Tak1*-deficient fibroblasts. Importantly, we found that p65 overexpression did not at all rescue TNF-induced cell death in *Tab2*-deficient fibroblasts ([Fig. 6 E](#fig6){ref-type="fig"}). Thus, enforced activation of NF-κB blocks only *Tak1* deficiency--caused apoptosis but does not affect RIPK3-dependent cell death in *Tab2*-deficient fibroblasts, and this allows us to investigate the role of *Tak1* in RIPK3-dependent cell death by blocking apoptosis caused by *Tak1* deficiency. TNF-induced RIPK3-dependent cell death may be through hyperactivation of TAK1 as we hypothesized or through TAK1-independent mechanisms. If hyperactivation of TAK1 is the mechanism, deletion of *Tak1* should rescue TNF-induced cell death in p65 overexpressing *Tab2*-deficient fibroblasts. Conversely, if *Tab2*-deficient fibroblasts died upon TNF treatment not solely through a TAK1-dependent mechanism, deletion of *Tak1* would not effectively rescue TNF-induced cell death in p65 overexpressing *Tab2*-deficient fibroblasts. We found that *Tak1* and *Tab2* double-deficient fibroblasts with a stable overexpression of p65 were completely resistant to TNF-induced cell death ([Fig. 6 E](#fig6){ref-type="fig"}). This result clearly indicates that TAK1 mediates TNF-induced cell death in *Tab2*-deficient fibroblasts.

![***Tak1* deletion rescues TNF-induced cell death in *Tab2*-deficient fibroblasts when apoptosis is blocked.** (A) To generate *Tab2* KO, *Tak1* Het, and *Tab2 Tak1* DKO fibroblasts, *Rosa26-CreERT Tab2^flox/flox^*, *Rosa26-CreERT Tak1^flox/+^Tab2^flox/flox^*, and *Rosa26-CreERT Tak1^flox/flox^Tab2^flox/flox^* dermal fibroblasts were treated with 0.1 µM 4-hydroxytamoxifen to induce the deletion of *Tak1* and *Tab2*. *Rosa26-CreERT Tab2^flox/flox^* dermal fibroblasts were treated with vehicle (EtOH) and studied in parallel as *Tab2* WT controls. Fibroblasts were stimulated with 200 ng/ml TNF for 24 h and cell viability was determined by the crystal violet assay (three independent experiments; mean ± SD; \*, P = 0.029; \*\*\*, P = 0. 00056). (B) *Tab2* KO *Tak1* Het and *Tab2 Tak1* DKO fibroblasts were pretreated with vehicle (DMSO) or Z-VAD (20 µM) for 1 h and stimulated with 200 ng/ml TNF for 6 h. Caspase-3 was analyzed by immunoblotting. Immunoblots of TAK1, TAB2, and β-actin are shown as controls. The asterisk indicates a nonspecific band. Caspase-8 activity in cellular extracts from samples treated with the same procedure was measured. Data are shown as caspase-8 activity relative to that in unstimulated *Tab2* KO *Tak1* Het fibroblasts (three independent experiments; mean ± SD; \*\*, P = 0.0019). (C) *Tab2* WT and *Tab2* KO fibroblasts were pretreated with vehicle (DMSO) or 5Z-7-Oxozeaenol (Zeaenol; 1 µM) for 1 h and stimulated with TNF (200 ng/ml) for 6 h. Immunoblots of TAB2 and β-actin are shown as controls. The asterisk indicates a nonspecific band. Caspase-8 activity in cellular extracts from samples treated with the same procedure was measured. Data are shown as caspase-8 activity relative to that in unstimulated *Tab2* WT fibroblasts (three independent experiments; mean ± SD; \*\*\*, P \< 0.001; P = 0.00038 and P = 0.000014 from the left). (D and E) *Tak1* WT, *Tak1* KO, *Tab2* WT, *Tab2* KO, *Tak1 Tab2* WT, and *Tak1 Tab2* DKO fibroblasts were stably transfected with p65. Immunoblots of p65, TAK1, TAB2, and β-actin are shown (D). Fibroblasts were stimulated with 200 ng/ml TNF for 24 h, and cell viability was determined by the crystal violet assay (E) (three independent experiments; mean ± SD; \*\*\*, P \< 0.001; N.S., not significant; P = 3E--05, P = 0.58, and P = 0.00015 from the left).](JCB_201305070_Fig6){#fig6}

TAK1 is hyperactivated by inhibition of caspases
------------------------------------------------

We asked whether TAK1 is hyperactivated under any physiological conditions other than *Tab2* deletion. Based on the results showing that TAK1 promotes RIPK3-dependent cell death, we hypothesized that necrosis-inducing conditions might be associated with hyperactivation of TAK1. The most well established condition to promote TNF-induced necrosis is inhibition of caspases, which occurs when viral-derived caspase inhibitors are introduced into cells. We examined whether TAK1 was activated by inhibition of caspases in fibroblasts. Inhibition of caspases (Z-VAD treatment) slightly activated TAK1 at 3--6 h after TNF treatment in wild-type fibroblasts, and inhibition of caspases in *Tab2*-deficient fibroblasts further up-regulated TAK1 activity ([Fig. 7, A and B](#fig7){ref-type="fig"}; 1--6 lanes from left). Thus, hyperactivation of TAK1 is associated with caspase inhibition and necrotic cell death. We next examined the mechanism of TAK1 hyperactivation. Because caspase inhibition upon TNF stimulation activates RIPK1 and RIPK3, we hypothesized that RIPK1 or RIPK3 or both are involved in the hyperactivation of TAK1. We first examined whether RIPK3 is required for TAK1 activation by using *Ripk3*-deficient dermal fibroblasts. *Ripk3* deficiency reduced TNF- and Z-VAD--induced TAK1 activation in *Tab2*-deficient fibroblasts ([Fig. 7 B](#fig7){ref-type="fig"}). This indicates that RIPK3 mediates the TAK1 hyperactivation. To examine the involvement of RIPK1, Nec-1 was used and we found that inhibition of RIPK1 also reduced TNF- and Z-VAD--induced TAK1 activation in *Tab2*-deficient fibroblasts ([Fig. 7 C](#fig7){ref-type="fig"}). These results suggest that both RIPK1 and RIPK3 are essential for TAK1 hyperactivation. To further investigate the contribution of RIPK1 and RIPK3 to TAK1 activation, we examined whether RIPK1 and/or RIPK3 can activate TAK1 using the overexpression system in HeLa cells ([Fig. 7 D](#fig7){ref-type="fig"}). As mentioned above, HeLa cells expressed endogenous RIPK1 ([Fig. 7 D](#fig7){ref-type="fig"}, fourth panel) but not RIPK3 ([@bib15]). Treatment of TNF, Smac mimetic, and Z-VAD activated overexpressed RIPK3 ([Fig. 7 D](#fig7){ref-type="fig"}, sixth panel, lane 8) and endogenous TAK1 ([Fig. 7 D](#fig7){ref-type="fig"}, top panel, lane 8). However, RIPK1 overexpression did not activate TAK1 even with treatment with TNF, Smac mimetic, and Z-VAD ([Fig. 7 D](#fig7){ref-type="fig"}, top panel, lane 4). This demonstrates that an active RIPK1 alone cannot activate TAK1. Interestingly, TNF-, Smac mimetic--, and Z-VAD--induced activation of TAK1 in RIPK3-expressing cells was completely blocked by Nec-1 ([Fig. 7 D](#fig7){ref-type="fig"}, top panel, lane 10). Nec-1 completely blocked activation of RIPK3 ([Fig. 7 D](#fig7){ref-type="fig"}, sixth panel, lanes 8 and 10). These data indicate that RIPK3 may be a direct activator and RIPK1 is required for activation of RIPK3. To further evaluate whether RIPK3 is a direct activator of TAK1, we incubated TAK1 immunopurified from TAK1-overexpressing HEK293 cells with RIPK1 or RIPK3, which was separately prepared from RIPK1- or RIPK3-overexpressing HEK293 cells. We found that the in vitro incubation of TAK1 with RIPK3 but not with RIPK1 elevated TAK1 activity ([Fig. 7 E](#fig7){ref-type="fig"}). These data confirm that RIPK3 is a direct activator of TAK1. We note that endogenous RIPK1 was co-precipitated with RIPK3 and was present in the in vitro kinase mixture ([Fig. 7 E](#fig7){ref-type="fig"}, bottom panel). This raises the possibility that RIPK1 may still participate in RIPK3-induced TAK1 activation through some mechanisms but not through direct activation of TAK1. We examined interaction among TAK1, RIPK1, and RIPK3 using a HEK293 overexpression system ([Fig. 7 F](#fig7){ref-type="fig"}). TAK1 and RIPK3 were not detectably associated when both proteins were overexpressed in HEK293 cells ([Fig. 7 F](#fig7){ref-type="fig"}, lane 6), but overexpression of RIPK1 induced an interaction between TAK1 and RIPK3 ([Fig. 7 F](#fig7){ref-type="fig"}, lane 8). Overexpression of RIPK1 also induced an interaction between RIPK3 and endogenous TAK1 ([Fig. 7 F](#fig7){ref-type="fig"}, lane 7). Thus, RIPK1 mediates interaction between TAK1 and RIPK3. These results demonstrate that RIPK1 contributes to activation of TAK1 by facilitating interaction between TAK1 and RIPK3 as well as activating RIPK3 in response to TNF, Smac mimetic, and Z-VAD. We describe that TAK1 activated RIPK3 in [Fig. 5](#fig5){ref-type="fig"}, in that endogenous RIPK1 was found to be present in the assay mixture. Thus, RIPK1 may also enhance TAK1-induced activation of RIPK3 by facilitating interaction between TAK1 and RIPK3. Collectively, TAK1 activates RIPK3, RIPK3 activates TAK1, and RIPK1 activates RIPK3 and facilitates interaction between TAK1 and RIPK3. We propose that TAK1, RIPK1, and RIPK3 are activated through a positive feedforward loop mechanism.

![**Inhibition of caspases hyperactivates TAK1 through RIPK1 and RIPK3.** (A) *Tab2* WT and *Tab2* KO fibroblasts were pretreated with vehicle (DMSO) or Z-VAD (20 µM) for 1 h and stimulated with TNF (20 ng/ml) for the indicated time periods, and TAK1 activation was determined by immunoblotting with anti--phospho-TAK1. TAB2 and TAK1 are shown as controls. (B) *Tab2* WT, *Tab2* KO, and *Ripk3*-deficient (*Ripk3* KO) and *Tab2* and *Ripk3*-deficinet (*Tab2 Ripk3* DKO) dermal fibroblasts were pretreated with vehicle (DMSO) or Z-VAD (20 µM) for 1 h and stimulated with TNF (20 ng/ml) for 6 h. TAK1 activation was determined by immunoblotting with anti--phospho-TAK1. TAK1, TAB2, RIPK3, and β-actin are shown as controls. The asterisk indicates a nonspecific band. (C) *Tab2* KO fibroblasts were pretreated with 20 µM Z-VAD and 30 µM Nec-1 for 1 h as indicated, then stimulated with 20 ng/ml TNF. TAK1 activation was determined by immunoblotting with anti--phospho-TAK1. Immunoblots of total TAK1 and RIPK1 are shown as controls. (D) HeLa cells were transfected with GPF-HA-RIPK1 (RIPK1), FLAG-RIPK3 (RIPK3), or control vectors (Vec) and pretreated with 30 µM Nec-1 for 1 h, then stimulated with 200 ng/ml TNF alone or together with 1 µM Smac mimetic and 20 µM Z-VAD (S/Z). TAK1 activation was determined by immunoblotting with anti--phospho-TAK1. Total amounts of TAK1, overexpressed RIPK1, endogenous RIPK1, and overexpressed RIPK3 and β-actin are shown. (E) The Flag-tagged TAK1 wild-type (TAK1), GFP- and HA-tagged *RIPK1* wild-type (RIPK1), or kinase-dead (K45A; RIPK1 KD), GFP-tagged *RIPK3* wild-type (RIPK3), or kinase-dead (D161N; RIPK3 KD) were separately expressed in HEK293 cells. TAK1, RIPK1, and RIPK3 were immunoprecipitated with anti-Flag, anti-HA, or anti-RIPK3 antibody, respectively. TAK1 was released from antibody beads and then mixed with RIPK1, RIPK1 KD, RIPK3, or RIPK3 KD immunoprecipitates as indicated. TAK1 activation was determined by immunoblotting with anti--phospho-TAK1. Protein amounts of TAK1, RIPK1, and RIPK3, and endogenous RIPK1 coprecipitated in RIPK3 precipitates were determined by immunoblotting. Density measurement was conducted using Photoshop CS3 and the relative ratio between phospho-TAK1 and total TAK1 to that in TAK1 expression alone (third lane from left) is shown. (F) HEK293 cells were transfected with DsRedMT7-TAK1 (TAK1), GFP-HA-RIPK1 (RIPK1), and Flag-RIPK3 (RIPK3) or control vectors, and total cell lysates were immunoprecipitated with anti-Flag antibody. RIPK3-binding proteins were detected by immunoblotting using anti-HA and anti-TAK1 antibodies. Immunoprecipitated RIPK3 was detected by anti-Flag.](JCB_201305070R_Fig7){#fig7}

Discussion
==========

TAK1 kinase switches between apoptosis and necrosis
---------------------------------------------------

As summarized in [Fig. 8](#fig8){ref-type="fig"}, the current study reveals that diminished TAK1 activity activates caspase-8, whereas hyperactivation of TAK1 promotes RIPK3-dependent necrosis. It has been established that a transient activation of TAK1 in response to TNF engages cell survival through induction of NF-κB and antioxidant enzymes ([@bib46]; [@bib40]). Thus, the level and timing of TAK1 activation determine whether cells are alive or undergo apoptosis or necrosis after TNF stimulation.

![**Models.** In wild-type cells, TAK1 is transiently activated upon TNF stimulation and inhibits caspase-8, which blunts the apoptosis pathway. *Tak1* deficiency activates TNF-induced caspase-8 apoptosis pathway, which is inhibitory to the RIPK3-dependent necrosis pathway. Hyperactivation of TAK1 blocks TNF-induced apoptosis and activates the RIPK1--RIPK3 necrotic pathway. TAK1--RIPK1--RIPK3 is activated by a positive feedforward loop mechanism.](JCB_201305070_Fig8){#fig8}

Relationship between caspase-8 deficiency and *Tak1* deficiency
---------------------------------------------------------------

Inhibition of caspases by gene deletion of either caspase-8 or its adaptor protein FADD causes RIPK1--RIPK3-dependent cell death ([@bib20]; [@bib38]; [@bib61]). Interestingly, mice having deletion of *Tak1*, caspase-8, or *Fadd* genes share similarity. Epidermal-specific deletion of caspase-8 causes severe inflammatory conditions in the skin in neonatal mice ([@bib25]), which resembles the skin in mice having epidermal-specific deletion of *Tak1* ([@bib39]). Caspase-8 deficiency is associated with abnormal vascular development during embryogenesis ([@bib20]), which is also seen in embryos with endothelial-specific deletion of *Tak1* ([@bib31]). Furthermore, intestinal epithelial-specific deletion of *Fadd* or caspase-8 causes ileitis ([@bib12]; [@bib57]), which is identical to intestinal epithelial-specific deletion of *Tak1* ([@bib22]). These might suggest that TAK1 is involved in maintenance of caspase-8 activity, which is pro-cell survival. However, as shown in the current study, caspases are activated after TNF stimulation in *Tak1*-deficient fibroblasts. Thus, the mechanisms of cell death in *Tak1* deficiency and caspase-8 deficiency are different. Indeed, abnormalities in embryogenesis by deletion of caspase-8 or *Fadd* are rescued by *Ripk3* gene deletion ([@bib20]; [@bib38]), but TNF-induced cell death in *Tak1*-deficient cells is not rescued by *Ripk3* deletion in vivo and in vitro as shown in the current study. [@bib55] also recently reported that *Ripk3* deletion did not rescue liver damage in *Tak1*-deficient liver. Thus, caspase-8 or *Fadd* deficiency kills cells through RIPK3-dependent necrosis, whereas TAK1 deficiency causes caspase-induced apoptosis. TNF is expressed at some levels in tissues, and kills cells, if caspase-8, *Fadd*, or *Tak1* gene is deleted, through two different mechanisms leading to similar outcomes.

The effect of caspase inhibition in *Tak1*-deficient cells
----------------------------------------------------------

To block TNF-induced apoptosis in *Tak1*-deficient cells, we initially used a pan-caspase inhibitor, Z-VAD. However, Z-VAD failed to rescue cell death in *Tak1*-deficient cells (Fig. S1 D). We assume that caspase inhibition by Z-VAD activates necrosis in response to TNF in *Tak1*-deficient cells, consistent with reports showing that Z-VAD does not block but rather enhances TNF-induced necrotic cell death ([@bib16]; [@bib6]; [@bib13]). NF-κB is known to up-regulate inhibitory molecules for caspase-8 such as c-FLIP and cIAPs ([@bib29]). In contrast to Z-VAD treatment, we show that overexpression of NF-κB could suppress apoptosis without activating necrosis ([Fig. 6](#fig6){ref-type="fig"}). What causes these different outcomes of Z-VAD treatment and NF-κB overexpression? TNF stimulation normally induces the formation of a complex containing RIPK1, RIPK3, FADD, c-FLIP, and caspase-8 ([@bib11]). [@bib8] described that c-FLIP makes a heterodimer with caspase-8 and prevents an active homodimer formation of caspase-8. The c-FLIP--caspase-8 heterodimer inhibits RIPK3, resulting in no activation of either caspase-8 or RIPK3. We found that the basal expression level of c-FLIP was reduced in *Tak1*-deficient cells, which was restored by NF-κB overexpression (Fig. S5). These data suggest that reduced c-FLIP expression and subsequent caspase-8 homodimer formation may be involved in TNF-induced caspase-8 activation in *Tak1*-deficient cells. In this context, restoration of c-FLIP by NF-κB overexpression inhibits the homodimer formation of caspase-8 and normalizes the complex composition so that RIPK3 is not activated. On the other hand, caspase-8 inhibition without restoration of c-FLIP in *Tak1*-deficient cells would activate RIPK3-dependent necrosis.

RIPK1-dependent caspase-8 activation in *Tak1*-deficient fibroblasts
--------------------------------------------------------------------

*Tak1*-deficient fibroblasts undergo apoptosis upon TNF stimulation. Our results clearly demonstrate that RIPK1 activity is required for this apoptosis. However, RIPK1 is not typically involved in death ligand--induced apoptosis ([@bib50]). Only when polyubiquitination of RIPK1 is blocked by inhibition of ubiquitination enzymes cIAPs or by mutation at the polyubiquitination site of RIPK1, RIPK1 becomes a pro-apoptotic and activates caspase-8 ([@bib35]; [@bib56]). Treatment of a cIAP inhibitor, Smac mimetic, together with TNF is well known to induce this type of apoptosis. Interestingly, we have previously reported that cIAPs are down-regulated by *Tak1* deletion in keratinocytes ([@bib30]). Thus, it is likely that TNF-induced apoptosis in *Tak1*-deficient fibroblasts is through a mechanism similar to that of Smac mimetic treatment.

Relationship between TAK1 and RIPK1--RIPK3
------------------------------------------

It has been shown that phosphorylation of RIPK1 and RIPK3 is important for stable RIPK1--RIPK3 complex formation and subsequent execution of necrotic cell death ([@bib5]; [@bib15]). RIPK1 kinase activity is required for RIPK3 phosphorylation, and reciprocally RIPK3 phosphorylates RIPK1 ([@bib5]). However, the mechanism by which these phosphorylation events are regulated was still elusive. We reveal that hyperactivation of TAK1 induces phosphorylation of RIPK3 even without TNF stimulation. This raises the possibility that TAK1 acts upstream of RIPK3. We also found that RIPK3 activation leads to hyperactivation of TAK1, suggesting that TAK1 is not only upstream of RIPK3 but also a target of RIPK3. Furthermore, we show that RIPK1 facilitates RIPK3-induced TAK1 activation, suggesting that TAK1--RIPK1--RIPK3 is activated in a positive feedforward mechanism. Our results demonstrate that TAK1 promotes RIPK1--RIPK3--necrosis; however, it is still not clear whether TAK1 is entirely required for this type of death. Inhibition of caspase in *Tak1*-deficient fibroblasts initially blocked but still induced cell death upon TNF stimulation in later time points (Fig. S1, B and D). Because treatment of Z-VAD and TNF normally activates RIPK3, this cell death is presumably RIPK3-dependent necrosis. Thus, TAK1 may not be required for RIPK3 activation under some circumstances. Alternatively, *Tak1* deficiency may cause RIPK3-independent cell death when caspases are inhibited. Further studies in cell death in *Tak1*-deficient cells will clarify contribution of TAK1 to RIPK3-dependent and potentially other types of cell death. In addition, further studies are required to define precise physical interactions and potential phosphorylation sites of TAK1, RIPK1, and RIPK3 using purified proteins. Our results identify TAK1--RIPK1--RIPK3 as a necrosis promoting protein kinase cascade.

Materials and methods
=====================

Mice and cell culture
---------------------

*Tab2*-floxed (*Tab2^flox/flox^*) mice ([@bib44]) were backcrossed for a minimum of five generations to C57BL/6 mice. Fibroblasts were isolated from the dermis of the neonatal mice and spontaneously immortalized in culture. *Tab2*-deficient fibroblasts were generated by infection of a retroviral vector for the expression of Cre recombinase. We isolated more than 10 independent clones of control and *Tab2*-deficient fibroblasts ([@bib4]), and we confirmed that all *Tab2*-deficient fibroblast clones were sensitive to TNF-induced cell death. Several double-deficient fibroblasts were generated by using mice having combinations of *Tab2^flox/flox^*, *Tak1^flox/flox^* ([@bib45]), and Ripk3^−/−^ mice (a gift from V.M. Dixit, Genentech, Inc., South San Francisco, CA; [@bib33]) and a deleter transgene, *Rosa26-CreERT* (The Jackson Laboratory; [@bib2]). Gene deletion was induced in vitro by incubation with 0.1 µM 4-hydroxytamoxifen for 3 d. Fibroblasts, HeLa, and HEK293 cells were cultured in DMEM with 10% bovine growth serum (Hyclone) and penicillin/streptomycin at 37°C in 5% CO~2~. *Alb.Cre* and *Tnfr1^−/−^* C57BL/6 mice were obtained from The Jackson Laboratory ([@bib42]; [@bib43]). Hepatocyte-specific *Tak1*-deficient *Alb.Cre Tak1^flox/flox^* (*Tak1^LPC-KO^*) mice, in a background of either *Tnfr1^−/−^* or *Ripk3^−/−^*, were generated and compared with *Alb.Cre Tak1^flox/flox^* in a wild-type background. To induce gene deletion in mice having *Rosa26-CreERT* transgene, mice were intraperitoneally injected with 50 mg/kg tamoxifen for three consecutive days. Mice were subjected to experiments at least two weeks after tamoxifen treatment to prevent a potential effect from acute Cre toxicity as described previously ([@bib48]). All animal experiments were conducted with the approval of the North Carolina State University Institutional Animal Care and Use Committee.

Antibodies, reagents, and plasmids
----------------------------------

Anti--phospho-TAK1 (T187) rabbit polyclonal antibody (Cell Signaling Technology) was used to detect the phosphorylated form of TAK1. Anti-TAK1, -TAB1, and -TAB2 rabbit polyclonal antibodies were described previously ([@bib34]; [@bib24]; [@bib47]). Anti-RIPK3 (R4277, rabbit polyclonal; Sigma-Aldrich), anti-RIPK1 (mouse monoclonal, BD), anti--caspase-3 (8G10, rabbit polyclonal; Cell Signaling Technology), anti-p65 (C20, rabbit polyclonal; Santa Cruz Biotechnology, Inc.), anti--β-actin (C5, mouse monoclonal; Sigma-Aldrich), anti-HA (HA.11, mouse monoclonal; Covance), and anti-FLAG (M2, mouse monoclonal; Sigma-Aldrich) were used. The reagents used were TNF (PeproTech), Z-VAD-fmk (Z-VAD; Enzo Life Sciences), and Necrostatin-1 (Nec-1; Enzo Life Sciences). Smac mimetic (C~2~-symmetric compound; [@bib28]) was a gift from X. Wang (University of Texas Southwestern Medical Center, Dallas, TX). Full-length TAK1 cDNA was subcloned into pCMV-DsRedMonomer-T7 vector to generate pCMV-DsRedMT7-TAK1. pCMV-TAB1 and pCMV-TAK1 ([@bib34]; [@bib18]) and HA-tagged RIPK3 expression plasmid (pCI-neo-RIPK3-HA, a gift from X. Wang) were used. GFP-tagged wild-type and kinase-dead (D161N) RIPK3 expression plasmid (pEGFP-N1-GFP-RIP3 and pEGFP-N1-GFP-RIP3 (D161N)) and GFP- and HA-tagged wild-type and kinase-dead (K45A) RIPK1 (pEGFP-N1-GFP-RIP1 and pEGFP-N1-GFP-RIP1 (K45A)) were a gift from F. Chan (University of Massachusetts Medical School, Worcester, MA; Addgene plasmids).

Crystal violet assay
--------------------

Cells were plated on 24-well dishes overnight at 37°C in 5% CO~2~ at a concentration of 10^4^ cells per well. Cells were either pretreated with Z-VAD or Nec-1 for 1 h and exposed to TNF for 24 h. Cells were fixed in 10% formalin and stained with 0.1% crystal violet. The dye was eluted and analyzed at 595 nm.

Caspase assay
-------------

Cell extracts were mixed with the substrate mixture (Caspase-Glo; Promega) for caspase-8 or caspase-3, and the cleaved substrates were determined according to the manufacturer's instructions.

Immunoblotting
--------------

Whole-cell extracts were prepared using an extraction buffer containing 20 mM Hepes, pH 7.4, 150 mM NaCl, 12.5 mM β-glycerophosphate, 1.5 mM MgCl~2~, 2 mM EGTA, 10 mM NaF, 2 mM DTT, 1 mM Na~3~VO~4~, 1 mM phenylmethylsulfonyl fluoride, 20 µM aprotinin, and 0.5% Triton X-100. Cell extracts were resolved on SDS-PAGE and transferred to Hypond-P membranes (GE Healthcare). The membranes were immunoblotted with various antibodies, and the bound antibodies were visualized with horseradish peroxidase--conjugated antibodies against rabbit or mouse IgG using the ECL Western blotting system (GE Healthcare).

Transmission electron microscopy
--------------------------------

Fibroblasts were suspended in McDowell and Trump's 4F:1G fixative. The samples were then suspended in 1% osmium tetroxide in 0.1 M phosphate buffer (pH 7.4) for 1 h, dehydrated, and infiltrated with Spurr resin. 90-nm ultra-thin sections were stained with uranyl acetate and analyzed through an electron microscope (FEI/Philips EM 208S/Morgagni) at 80 kV.

*Ripk3* knockdown
-----------------

Two different *Ripk3* and nontargeting control siRNAs were generated (*Ripk3* siRNA-1 \[\#1\], 5′-GAGCTGTTATTTGATGTCAACCTGA-3′; *Ripk3* siRNA-2 \[\#2\], 5′-TGGCACTCCTCAGATTCCACATACT-3′; and non-targeting siRNA, 5′-UUCUCCGAACGUGUCACGU-3′). Fibroblasts were transfected with the siRNAs using Lipofectamine 2000 (Invitrogen).

Dephosphorylation of RIPK3
--------------------------

Cell lysates from HeLa cells were incubated with lambda protein phosphatase (New England Biolabs, Inc.) for 4 h at 30°C in a buffer containing 1 mM MnCl~2~ according to the manufacturer's instructions, and analyzed by immunoblotting.

Liver damage analysis
---------------------

Spontaneous liver injury was examined at 1--2 months of age. For acute liver injury model, 4--7-mo-old mice were intraperitoneally injected with LPS at 10 mg/kg. Liver specimens were fixed in 4% paraformaldehyde, and paraffin sections were subjected to TUNEL (Promega) staining according to the manufacturer's protocol. Serum ALT levels were measured using an ALT assay kit (BioVision).

Intradermal TNF injection
-------------------------

Mice were anesthetized by intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine. After shaving hair, 1 µg of TNF was intradermally injected to the skin. After 6 h, skin samples were collected.

Wound surgery
-------------

Mice were anesthetized and a skin wound was generated using a disposable biopsy punch (6.0 mm; Sklar Instruments). The wound area was monitored and measured every day, and wound closure was expressed as a percentage of initial wound size.

Microscopy and image analysis
-----------------------------

TUNEL staining was observed with 20× (UPlanFI; Olympus) and 40× (UPlanFLN; Olympus) objectives, and images were acquired using a fluorescence microscope (model BX41; Olympus) and camera (model XM10; Olympus) at room temperature with a DAPI or FITC filter. 3--10 immunofluorescent images per mouse were randomly photographed, and at least 1,000 DAPI-stained cells per mouse were counted. Quantitative results were generated from the counted numbers in 3--6 mice from independent experiments. Bright-field images were acquired with a 20× (LCAchN; Olympus) objective using an inverted microscope (model CKS41; Olympus) at room temperature. Image analysis was performed using cellSens Standard (Olympus) image analysis software.

Flow cytometric analysis
------------------------

HeLa cells and dermal fibroblasts were transfected with 1 µg of plasmids using Lipofectamine 2000. At 48 h after transfection, cells were stimulated with TNF, Smac mimetic, and Z-VAD for 6 h. Cell death was analyzed by fixable viability dye eFluor 780 (eBioscience) at 1 µl/ml and Pacific Blue--annexin V (Invitrogen). Stained cells were analyzed by a flow cytometer (LSR II; BD). Data were analyzed using FlowJo software (Tree Star).

Immunoprecipitation and in vitro kinase assay
---------------------------------------------

HEK293 cells were transfected with plasmids using the standard calcium phosphate method. Cell lysates were prepared in the extraction buffer described above. Flag-tagged TAK1, GFP-HA-tagged RIPK1, and GFP-tagged RIPK3 were immunoprecipitated with specific antibodies for 3 h at 4°C (kinase assay) or overnight at 4°C. The resulting immune complexes were washed with IP washing buffer (20 mM Hepes, pH 7.4, 10 mM MgCl~2~, and 500 mM NaCl) three times followed by a wash with kinase buffer (10 mM Hepes, pH 7.4, 1 mM DTT, and 5 mM MgCl~2~). TAK1 complex was released from antibody beads by incubation with 100 µM Flag peptide. For the kinase assay using RIPK3 as a substrate, TAK1 was pre-activated by incubation in kinase buffer with 1 mM ATP for 30 min at 30°C as described previously ([@bib24]) and washed once with kinase butter. The kinase and substrate were mixed and incubated in kinase buffer supplemented with 200 µM ATP and 5 µCi γ-\[^32^P\]ATP for 30 min at 30°C. Samples were resolved on SDS-PAGE and exposed to autoradiographic films or subjected to immunoblotting.

Retroviral infection
--------------------

Retroviral vectors for p65 (pMXpuro-p65) were generated by inserting p65 cDNA into the retroviral vector pMX-puro. PLAT-E cells ([@bib32]) were transiently transfected with pMX-puro-p65. After 48 h culture, the growth medium containing the retrovirus was collected and filtered with a 0.45-µm cellulose acetate membrane to remove packaging cells. Fibroblasts were incubated with the collected virus-containing medium with 10 µg/ml polybrene for 24 h. Uninfected cells were removed by puromycin selection.

Statistical analyses
--------------------

Statistical analyses were performed using two-tailed Student's *t* test or one-way ANOVA for comparing the means of two or multiple groups, respectively. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; N.S., not significant when P \> 0.05.

Online supplemental material
----------------------------

Fig. S1 A shows TNF-induced hyperactivation of TAK1 in *Tab2*-deficient fibroblasts. Fig. S1 B shows bright-field images of *Tak1*- and *Tab2*-deficient fibroblasts after TNF stimulation. Fig. S1 C shows TEM images of *Tak1*- and *Tab2*-deficient fibroblasts after TNF stimulation. Fig. S1 D shows that Z-VAD does not inhibit TNF-induced cell death in *Tak1*-deficient fibroblasts. Fig. S2 A shows that Nec-1 blocks TNF-induced cell death in *Tak1*-deficient fibroblasts. Fig. S2 B shows that *Tab2* and *Ripk3* double-deficient fibroblasts are completely resistant to TNF-induced cell death. Fig. S3 shows that Ripk3 deletion does not rescue chronic and acute liver injury in liver-specific *Tak1*-deficient mice. Fig. S4 shows that overexpression of an active TAK1 induces RIPK3-dependent cell death in fibroblasts. Fig. S5 shows that cFLIP is reduced in *Tak1*-deficient fibroblasts and is restored by p65 overexpression. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201305070/DC1>.
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